TFEB and metabolic dysfunction-associated steatohepatitis: Our study found that ponatinib could effectively ameliorate hepatic steatosis, inflammation and fibrosis in MCD-induced NASH mice by enhancing autophagy through increasing TFEB expression, and thus ponatinib may be a promising drug for the treatment of NASH (Figure 9, Graphical abstract).